Oliver Fetzer, Ph.D., MBA


Dr. Fetzer has served as CEO and Board Member of Synthetic Genomics since November 2014.  Previously, Dr. Fetzer served as President and CEO of Cerulean Pharma Inc. for five years, a pharmaceutical company that develops nanoparticle drug conjugate oncology therapeutics. Under Dr. Fetzer’s leadership, Cerulean advanced from a pre-clinical platform company to become a publicly-traded clinical development stage company with a pipeline of product candidates. Prior to Cerulean Pharma, Dr. Fetzer served for five years in a variety of positions of increasing responsibility at Cubist Pharmaceuticals, Inc., including Senior Vice President, Corporate Development and Chief Business Officer, and Senior Vice President, Corporate Development and Research & Development. Dr. Fetzer began his career at the Boston Consulting Group (BCG), a global leading management consulting firm, where he advanced over nine years from Consultant to Project Leader, Principal, and ultimately Partner and Managing Director.

Dr. Fetzer has served on the board of Tecan Group AG since 2011 and the board of Arena Pharmaceuticals, Inc. since 2017.  He served on the boards of Auxilium Pharmaceuticals, Inc. from 2005 to 2015 and Cerulean Pharma, Inc. from 2009 to 2014. Dr. Fetzer received a B.S. in Biochemistry from the College of Charleston, his Ph.D. in Pharmaceutical Sciences from the Medical University of South Carolina, and an MBA from Carnegie Mellon University.